Your browser is no longer supported. Please, upgrade your browser.
Settings
ALDX [NASD]
Aldeyra Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.02 Insider Own1.70% Shs Outstand45.63M Perf Week-4.80%
Market Cap712.33M Forward P/E- EPS next Y-1.14 Insider Trans367.23% Shs Float39.44M Perf Month1.49%
Income-39.00M PEG- EPS next Q-0.24 Inst Own60.40% Short Float11.00% Perf Quarter2.59%
Sales- P/S- EPS this Y50.70% Inst Trans39.70% Short Ratio1.87 Perf Half Y69.28%
Book/sh2.76 P/B4.45 EPS next Y-14.00% ROA-39.90% Target Price- Perf Year171.90%
Cash/sh- P/C- EPS next 5Y- ROE-50.70% 52W Range3.95 - 15.95 Perf YTD79.15%
Dividend- P/FCF- EPS past 5Y4.60% ROI- 52W High-24.98% Beta1.75
Dividend %- Quick Ratio13.30 Sales past 5Y- Gross Margin- 52W Low202.91% ATR0.55
Employees11 Current Ratio13.30 Sales Q/Q- Oper. Margin- RSI (14)46.07 Volatility4.00% 4.07%
OptionableYes Debt/Eq0.12 EPS Q/Q26.80% Profit Margin- Rel Volume0.20 Prev Close12.29
ShortableYes LT Debt/Eq0.08 EarningsMay 06 BMO Payout- Avg Volume2.32M Price11.97
Recom1.50 SMA20-1.70% SMA50-1.17% SMA20023.82% Volume232,805 Change-2.64%
Feb-08-21Initiated H.C. Wainwright Buy $26
Dec-16-20Initiated Berenberg Buy $32
Oct-30-20Initiated Jefferies Buy $24
Oct-16-20Initiated BTIG Research Buy $29
Sep-22-20Initiated Alliance Global Partners Buy $32
May-12-20Initiated Oppenheimer Outperform $12
Dec-04-18Initiated Citigroup Buy $23
Sep-26-18Reiterated Cantor Fitzgerald Overweight $23 → $30
Sep-13-18Initiated Janney Buy
Jan-26-18Initiated Seaport Global Securities Buy $13
Sep-26-16Initiated H.C. Wainwright Buy $18
Jul-01-16Initiated Stifel Buy $16
Jul-01-15Initiated Canaccord Genuity Buy $16
Mar-25-15Initiated Chardan Capital Markets Buy $16
Mar-20-15Reiterated H.C. Wainwright Buy $13 → $14
Nov-18-14Initiated H.C. Wainwright Buy $13
Jun-19-14Initiated Aegis Capital Buy $35
May-27-21 08:00AM  
May-06-21 09:31PM  
07:00AM  
06:15AM  
Apr-29-21 08:00AM  
Apr-28-21 06:31PM  
12:53PM  
06:10AM  
Apr-27-21 04:01PM  
11:06AM  
07:40AM  
07:00AM  
Apr-26-21 04:05PM  
Mar-11-21 07:00PM  
07:00AM  
05:15AM  
Mar-10-21 08:00AM  
Mar-09-21 08:34AM  
Mar-04-21 08:00AM  
Mar-02-21 08:00AM  
Feb-18-21 08:00AM  
Feb-07-21 11:18PM  
Feb-04-21 08:00AM  
Jan-20-21 07:00AM  
Jan-13-21 09:36PM  
04:01PM  
Jan-08-21 08:00AM  
Jan-07-21 07:00AM  
Jan-06-21 04:30PM  
Dec-22-20 08:00AM  
Dec-17-20 08:00AM  
Dec-16-20 09:18AM  
Dec-08-20 08:00AM  
Nov-13-20 08:00AM  
Nov-10-20 05:45AM  
Nov-05-20 07:00AM  
06:15AM  
Nov-04-20 08:00AM  
Oct-30-20 09:22PM  
Oct-29-20 08:00AM  
Oct-22-20 08:00AM  
Oct-16-20 04:20PM  
Oct-13-20 02:38PM  
Oct-02-20 11:30AM  
Sep-30-20 07:55AM  
Sep-29-20 10:30AM  
Sep-16-20 11:30AM  
08:00AM  
Sep-10-20 08:00AM  
Sep-09-20 08:00AM  
Sep-03-20 08:00AM  
Aug-25-20 11:30AM  
Aug-12-20 12:00PM  
Aug-06-20 10:09AM  
07:00AM  
Aug-04-20 10:07AM  
08:00AM  
Jul-30-20 08:00AM  
Jul-14-20 08:00AM  
04:32AM  
Jul-13-20 04:05PM  
Jul-07-20 09:28PM  
08:00AM  
Jul-03-20 11:15AM  
Jul-01-20 09:36AM  
Jun-22-20 12:00PM  
Jun-18-20 10:12AM  
Jun-15-20 08:00AM  
Jun-10-20 08:37PM  
Jun-07-20 06:28PM  
Jun-04-20 08:00AM  
Jun-03-20 09:04AM  
08:00AM  
May-27-20 09:49AM  
May-20-20 05:24PM  
08:12AM  
07:00AM  
01:48AM  
May-19-20 04:05PM  
May-15-20 08:53AM  
May-14-20 10:14AM  
May-13-20 12:00PM  
08:17AM  
May-07-20 07:00AM  
Apr-16-20 06:35AM  
Apr-15-20 09:47AM  
Apr-14-20 08:00AM  
Apr-01-20 01:42AM  
Mar-24-20 12:00PM  
08:00AM  
Mar-18-20 06:13AM  
Mar-12-20 07:00AM  
06:59AM  
Mar-05-20 08:00AM  
Mar-03-20 08:00AM  
Feb-24-20 08:00AM  
Feb-11-20 08:00AM  
Jan-28-20 08:00AM  
Jan-21-20 08:00AM  
Jan-14-20 08:00AM  
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerMay 03Buy12.501,200,00015,000,0009,903,879May 04 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerJan 19Buy9.501,368,42113,000,0008,703,879Jan 21 05:24 PM
PERCEPTIVE ADVISORS LLC10% OwnerJan 08Buy9.34550,0005,137,6687,335,458Jan 11 09:53 PM
PERCEPTIVE ADVISORS LLC10% OwnerJan 07Buy8.13500,0004,065,0006,785,458Jan 11 09:53 PM
PERCEPTIVE ADVISORS LLC10% OwnerJul 09Buy4.253,200,00013,600,0006,285,458Jul 13 04:30 PM